EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1064	trotter.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 16:25
L3	12	l1 and tyrosine.ti.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 16:25

=> b reg
FILE 'REGISTRY' ENTERED AT 11:05:24 ON 21 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6
DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta l9
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L9 19 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 17040 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

=> d bib abs hitstr retable l18
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:05:57 ON 21 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Feb 2007 VOL 146 ISS 9
FILE LAST UPDATED: 19 Feb 2007 (20070219/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitstr retable l18

L18 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:836790 HCAPLUS
DN 139:337988
TI Preparation of 1,2,3,4,5,6-hexahydro-5,2-(epiminomethano)-3-benzazocine
derivatives as tyrosine kinase inhibitors
IN **Trotter, B. Wesley**
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003086315	A2	20031023	2003WO-US12457	20030408 <--
	WO2003086315	A3	20040108		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2480758	A1	20031023	2003CA-2480758	20030408 <--
	AU2003223689	A1	20031027	2003AU-0223689	20030408 <--
	EP---1496907	A2	20050119	2003EP-0719886	20030408 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP2005528387	T	20050922	2003JP-0583340	20030408 <--
	US2005227988	A1	20051013	2004US-0510610	20041008 <--
PRAI	2002US-372232P	P	20020412 <--		
	2003WO-US12457	W	20030408 <--		

OS MARPAT 139:337988
GI



Q= $-(CR^{1?}{}_2)_n-X-(CR^{1?}{}_2)_p-V-(R^2)_q$

AB The present invention relates to benzazocine compds. [I; wherein R1a = H, (un)substituted C1-6 alkyl, OR4; R1b = H, (un)substituted C1-6 alkyl; X = a bond, CO, O, NR4, S(O)mR4, CO2R4, CON(R4)2; R1 = H, halo, OR4, NO2, S(O)mR4, cyano, each (un)substituted C1-10 alkyl, aryl, C2-6 alkenyl, C3-10 cycloalkyl, C2-6 alkynyl, or heterocyclyl, COR4, CO2R4, CON(R4)2, S(O)mN(R4)2, N(R4)2; V = H, CF3, aryl, heterocyclyl, C3-10 cycloalkyl; R2 = H, (un)substituted C1-10 alkyl, (CR1b)tOR4, halo, cyano, NO2, CF3, (CR1b)tN(R4)2, CO2R4, COR4, SO2R4, (CR1b)tNR4(CR1b)tR5, (CR1b)tS(O)mNR4, CO2R4, NR4COR4, each (un)substituted aryl or heterocyclyl; R4 = H, each (un)substituted C1-10 alkyl, C3-10 cycloalkyl, aryl, or heterocyclyl, CF3; R5 = each (un)substituted aryl or heterocyclyl; m = 0, 1, or 2; n, p, q, t = 0 to 6] or pharmaceutically acceptable salts or stereoisomers thereof. These compds. are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type tyrosine kinases (RTK) selected from insulin receptor (IR) kinase, insulin-like growth factor I receptor (IGF-IR) kinase and IRR receptor tyrosine kinase and non-receptor type tyrosine kinases (no data). They are useful for treating protein kinase, in particular RTK-related disorders such as cancer, diabetes, an autoimmune disorder, a hyperproliferation disorder, aging, acromegaly, and Crohn's disease and also treating retinal vascularization.

IT **615557-39-6P 615557-40-9P 615557-41-0P**
615557-42-1P 615557-43-2P 615557-44-3P
615557-45-4P 615557-46-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydro(epiminomethano)benzazocine'derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 615557-39-6 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-11-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 615557-40-9 HCAPLUS

CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 615557-41-0 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3,11-bis[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 615557-42-1 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3-acetyl-11-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 615557-43-2 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3-acetyl-11-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 615557-42-1
CMF C21 H23 Br N2 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 615557-44-3 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro-11-methyl- (9CI) (CA INDEX NAME)



RN 615557-45-4 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3-[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



RN 615557-46-5 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 3,11-bis[(3-bromophenyl)methyl]-1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



IT **615557-51-2P 615557-52-3P 615557-53-4P**
615557-54-5P 615557-55-6P 615557-56-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydro(epiminomethano)benzazocine derivs. as tyrosine kinase inhibitors for treating receptor type tyrosine kinase-related disorders)

RN 615557-51-2 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine-4,12(1H)-dione, 2,3,5,6-tetrahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)



RN 615557-52-3 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)



RN 615557-53-4 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-11-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 615557-54-5 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 615557-55-6 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine-3,11(2H)-dicarboxylic acid, 1,4,5,6-tetrahydro-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 615557-56-7 HCAPLUS
CN 5,2-(Iminomethano)-3-benzazocine, 1,2,3,4,5,6-hexahydro- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:16:22 ON 21 FEB 2007)

FILE 'REGISTRY' ENTERED AT 09:16:31 ON 21 FEB 2007
L1 STR
L2 0 L1

FILE 'HCAPLUS' ENTERED AT 09:23:31 ON 21 FEB 2007
L3 1 US20050227988/PN OR (US2004-510610 OR WO2003-US12457 OR US2002-
E TROTTER B/AU
L4 30 E5-7
E TROTTER W/AU

FILE 'REGISTRY' ENTERED AT 09:25:24 ON 21 FEB 2007

FILE 'HCAPLUS' ENTERED AT 09:25:29 ON 21 FEB 2007
L5 TRA L3 1- RN : 36 TERMS

FILE 'REGISTRY' ENTERED AT 09:25:30 ON 21 FEB 2007
L6 36 SEA L5
L7 22 L6 AND N/ELS
L8 20 NC2NC2-C6-NC7/ES OR 2492.8.1/RID
L9 19 L1 FULL
L10 14 L9 AND L6
L11 5 L9 NOT L10

FILE 'HCAPLUS' ENTERED AT 10:03:22 ON 21 FEB 2007
L12 1 L10

FILE 'HCAOLD' ENTERED AT 10:03:33 ON 21 FEB 2007
L13 0 L10

FILE 'USPATFULL, USPAT2' ENTERED AT 10:03:41 ON 21 FEB 2007
L14 1 L10

FILE 'MEDLINE' ENTERED AT 10:04:31 ON 21 FEB 2007
L15 0 L10

FILE 'BIOSIS' ENTERED AT 10:04:37 ON 21 FEB 2007
L16 0 L10

```
     FILE 'EMBASE' ENTERED AT 10:04:43 ON 21 FEB 2007
L17           0 L10

     FILE 'REGISTRY' ENTERED AT 10:05:08 ON 21 FEB 2007
                SAV TEM L9 J610B/A

     FILE 'HCAPLUS' ENTERED AT 10:05:38 ON 21 FEB 2007
L18           1 L12 AND L3-4

     FILE 'REGISTRY' ENTERED AT 10:20:11 ON 21 FEB 2007
L19           6 615557-51-2 OR  615557-52-3 OR 615557-53-4 OR 615557-54-5 OR 61

=>
```